tradingkey.logo

Veracyte Inc

VCYT
36.190USD
+1.330+3.82%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
2.86BMarktkapitalisierung
93.48KGV TTM

Veracyte Inc

36.190
+1.330+3.82%

mehr Informationen über Veracyte Inc Unternehmen

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.

Veracyte Inc Informationen

BörsenkürzelVCYT
Name des UnternehmensVeracyte Inc
IPO-datumOct 30, 2013
CEOStapley (Marc A)
Anzahl der mitarbeiter824
WertpapierartOrdinary Share
GeschäftsjahresendeOct 30
Addresse6000 Shoreline Court, Suite 300
StadtSOUTH SAN FRANCISCO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94080
Telefon16502436300
Websitehttps://www.veracyte.com/
BörsenkürzelVCYT
IPO-datumOct 30, 2013
CEOStapley (Marc A)

Führungskräfte von Veracyte Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
85.35K
-15582.00%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
50.97K
-11473.00%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
32.81K
+9321.00%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
27.84K
+4732.00%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
17.89K
-14302.00%
Mr. Jens Holstein
Mr. Jens Holstein
Independent Director
Independent Director
15.73K
-10000.00%
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Chief Financial Officer
Chief Financial Officer
4.31K
-16662.00%
Mr. John Leite, Ph.D.
Mr. John Leite, Ph.D.
Global Chief Commercial Officer
Global Chief Commercial Officer
2.81K
-5709.00%
Ms. Annie Mcguire
Ms. Annie Mcguire
Chief Human Resources Officer, General Counsel
Chief Human Resources Officer, General Counsel
2.24K
-2160.00%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Director
Independent Director
2.08K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
85.35K
-15582.00%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
50.97K
-11473.00%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
32.81K
+9321.00%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
27.84K
+4732.00%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
17.89K
-14302.00%
Mr. Jens Holstein
Mr. Jens Holstein
Independent Director
Independent Director
15.73K
-10000.00%

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2024
FY2023
FY2022
FY2021
FY2020
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States
423.54M
95.01%
International
22.23M
4.99%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Fri, Jan 9
Aktualisiert: Fri, Jan 9
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
14.32%
The Vanguard Group, Inc.
10.74%
Artisan Partners Limited Partnership
7.92%
Fidelity Management & Research Company LLC
7.27%
State Street Investment Management (US)
5.31%
Andere
54.44%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
14.32%
The Vanguard Group, Inc.
10.74%
Artisan Partners Limited Partnership
7.92%
Fidelity Management & Research Company LLC
7.27%
State Street Investment Management (US)
5.31%
Andere
54.44%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
68.34%
Investment Advisor/Hedge Fund
35.80%
Hedge Fund
4.58%
Research Firm
2.29%
Pension Fund
1.93%
Bank and Trust
0.55%
Individual Investor
0.42%
Sovereign Wealth Fund
0.06%
Family Office
0.04%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
652
89.70M
113.47%
-3.53M
2025Q3
616
87.37M
110.53%
-1.45M
2025Q2
598
84.22M
107.53%
-1.90M
2025Q1
612
85.86M
109.67%
-679.43K
2024Q4
593
81.64M
104.75%
-2.62M
2024Q3
567
81.88M
106.62%
-2.30M
2024Q2
533
81.65M
106.83%
-3.86M
2024Q1
532
81.30M
103.75%
+1.22M
2023Q4
524
76.49M
104.40%
-3.87M
2023Q3
520
77.05M
105.90%
-3.78M
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
11.32M
14.32%
+5.19M
+84.79%
Sep 30, 2025
The Vanguard Group, Inc.
8.49M
10.74%
+403.74K
+5.00%
Sep 30, 2025
Artisan Partners Limited Partnership
7.37M
9.32%
+1.05M
+16.59%
Sep 30, 2025
Fidelity Management & Research Company LLC
5.75M
7.27%
-1.18M
-17.05%
Sep 30, 2025
State Street Investment Management (US)
4.20M
5.31%
+1.03M
+32.49%
Sep 30, 2025
ARK Investment Management LLC
4.47M
5.65%
+665.69K
+17.52%
Sep 30, 2025
Wellington Management Company, LLP
3.37M
4.27%
-100.55K
-2.89%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
3.12M
3.94%
+95.66K
+3.17%
Sep 30, 2025
ArrowMark Colorado Holdings, LLC
2.55M
3.22%
-33.08K
-1.28%
Sep 30, 2025
Geode Capital Management, L.L.C.
1.89M
2.39%
-39.95K
-2.07%
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Invesco Biotechnology & Genome ETF
4.35%
ARK Genomic Revolution ETF
3.68%
First Trust NYSE Arca Biotechnology Index Fund
3.48%
Global X Genomics & Biotechnology ETF
3.13%
ROBO Global Healthcare Technology & Innovation ETF
2.19%
Invesco S&P SmallCap 600 Pure Growth ETF
1.97%
Invesco S&P SmallCap Health Care ETF
1.74%
Franklin Genomic Advancements ETF
1.45%
ROBO Global Artificial Intelligence ETF
1.43%
ARK Innovation ETF
1.24%
Mehr Anzeigen
Invesco Biotechnology & Genome ETF
Anteil4.35%
ARK Genomic Revolution ETF
Anteil3.68%
First Trust NYSE Arca Biotechnology Index Fund
Anteil3.48%
Global X Genomics & Biotechnology ETF
Anteil3.13%
ROBO Global Healthcare Technology & Innovation ETF
Anteil2.19%
Invesco S&P SmallCap 600 Pure Growth ETF
Anteil1.97%
Invesco S&P SmallCap Health Care ETF
Anteil1.74%
Franklin Genomic Advancements ETF
Anteil1.45%
ROBO Global Artificial Intelligence ETF
Anteil1.43%
ARK Innovation ETF
Anteil1.24%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI